These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 37402003

  • 41. The Accuracy and Clinical Relevance of the Multi-echo Dixon Technique for Evaluating Changes to Hepatic Steatosis in Patients with Non-alcoholic Fatty Liver Disease Treated with Formulated Food.
    Yang Y, Xu K, Chen X, Ding J, Shi J, Li J.
    Magn Reson Med Sci; 2023 Apr 01; 22(2):263-271. PubMed ID: 35676065
    [Abstract] [Full Text] [Related]

  • 42. Optimization of region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification.
    Hong CW, Wolfson T, Sy EZ, Schlein AN, Hooker JC, Fazeli Dehkordy S, Hamilton G, Reeder SB, Loomba R, Sirlin CB.
    J Magn Reson Imaging; 2018 Apr 01; 47(4):988-994. PubMed ID: 28842937
    [Abstract] [Full Text] [Related]

  • 43. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.
    Han A, Zhang YN, Boehringer AS, Montes V, Andre MP, Erdman JW, Loomba R, Valasek MA, Sirlin CB, O'Brien WD.
    Radiology; 2020 Apr 01; 295(1):106-113. PubMed ID: 32013792
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Susceptibility based multiparametric quantification of liver disease: Non-invasive evaluation of steatosis and iron overload.
    Uhrig M, Mueller J, Longerich T, Straub BK, Buschle LR, Schlemmer HP, Mueller S, Ziener CH.
    Magn Reson Imaging; 2019 Nov 01; 63():114-122. PubMed ID: 31425813
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Quantification of liver fat with respiratory-gated quantitative chemical shift encoded MRI.
    Motosugi U, Hernando D, Bannas P, Holmes JH, Wang K, Shimakawa A, Iwadate Y, Taviani V, Rehm JL, Reeder SB.
    J Magn Reson Imaging; 2015 Nov 01; 42(5):1241-8. PubMed ID: 25828696
    [Abstract] [Full Text] [Related]

  • 52. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB, NASH Clinical Research Network.
    Gastroenterology; 2017 Sep 01; 153(3):753-761. PubMed ID: 28624576
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Ultrasound Shear Wave Attenuation Imaging for Grading Liver Steatosis in Volunteers and Patients With Non-alcoholic Fatty Liver Disease: A Pilot Study.
    Yazdani L, Rafati I, Gesnik M, Nicolet F, Chayer B, Gilbert G, Volniansky A, Olivié D, Giard JM, Sebastiani G, Nguyen BN, Tang A, Cloutier G.
    Ultrasound Med Biol; 2023 Oct 01; 49(10):2264-2272. PubMed ID: 37482477
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Intra-individual Comparisons of the Ultrasound-Guided Attenuation Parameter and the Magnetic Resonance Imaging-Based Proton Density Fat Fraction Using Bias and Precision Statistics.
    Kumada T, Ogawa S, Goto T, Toyoda H, Yasuda S, Ito T, Yasuda E, Akita T, Tanaka J.
    Ultrasound Med Biol; 2022 Aug 01; 48(8):1537-1546. PubMed ID: 35613974
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R.
    J Hepatol; 2019 Jan 01; 70(1):133-141. PubMed ID: 30291868
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.